Equities Analysts Offer Predictions for Coherus BioSciences, Inc.’s FY2028 Earnings (NASDAQ:CHRS)

Coherus BioSciences, Inc. (NASDAQ:CHRS) – Research analysts at HC Wainwright issued their FY2028 earnings per share (EPS) estimates for Coherus BioSciences in a research report issued on Monday, September 16th. HC Wainwright analyst D. Tsao expects that the biotechnology company will post earnings per share of $0.08 for the year. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Coherus BioSciences’ current full-year earnings is ($1.07) per share.

Coherus BioSciences (NASDAQ:CHRS) last posted its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.10. The company had revenue of $64.98 million during the quarter, compared to the consensus estimate of $57.08 million.

Several other research firms also recently weighed in on CHRS. StockNews.com downgraded shares of Coherus BioSciences from a “buy” rating to a “hold” rating in a research note on Friday, September 6th. Robert W. Baird reduced their price objective on Coherus BioSciences from $9.00 to $8.00 and set an “outperform” rating on the stock in a report on Monday, July 1st. Finally, UBS Group cut Coherus BioSciences from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $4.00 to $1.50 in a report on Friday, August 16th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $6.92.

Coherus BioSciences Price Performance

Coherus BioSciences stock opened at $1.13 on Thursday. The stock has a market cap of $129.64 million, a price-to-earnings ratio of -1.45 and a beta of 0.66. The firm has a 50-day moving average of $1.41 and a two-hundred day moving average of $1.80. Coherus BioSciences has a 1 year low of $1.01 and a 1 year high of $4.73.

Hedge Funds Weigh In On Coherus BioSciences

Institutional investors have recently bought and sold shares of the business. CM Management LLC boosted its position in Coherus BioSciences by 10.0% during the 2nd quarter. CM Management LLC now owns 1,100,000 shares of the biotechnology company’s stock valued at $1,903,000 after acquiring an additional 100,000 shares in the last quarter. AQR Capital Management LLC bought a new stake in Coherus BioSciences during the second quarter valued at about $1,246,000. Marshall Wace LLP grew its stake in Coherus BioSciences by 177.3% in the second quarter. Marshall Wace LLP now owns 420,326 shares of the biotechnology company’s stock valued at $727,000 after purchasing an additional 268,763 shares during the last quarter. Renaissance Technologies LLC raised its holdings in Coherus BioSciences by 159.2% in the second quarter. Renaissance Technologies LLC now owns 394,828 shares of the biotechnology company’s stock worth $683,000 after purchasing an additional 242,500 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its position in shares of Coherus BioSciences by 26.0% during the second quarter. Bank of New York Mellon Corp now owns 389,225 shares of the biotechnology company’s stock valued at $673,000 after buying an additional 80,222 shares during the last quarter. 72.82% of the stock is owned by hedge funds and other institutional investors.

About Coherus BioSciences

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.